Stephen W. Webster - 28 Jul 2021 Form 4 Insider Report for Nabriva Therapeutics plc

Role
Director
Signature
/s/ Robert Crotty, by power of attorney
Issuer symbol
N/A
Transactions as of
28 Jul 2021
Net transactions value
$0
Form type
4
Filing time
30 Jul 2021, 20:19:32 UTC
Previous filing
28 Jun 2021
Next filing
04 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRV Ordinary Shares Award $0 +17,500 +686% $0.000000 20,050 28 Jul 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBRV Share Options Award $0 +35,000 $0.000000 35,000 28 Jul 2021 Ordinary Shares 35,000 $1.08 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units.
F2 The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020.
F3 The option was granted on July 28, 2021.
F4 One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc.